Back to top
more

DaVita (DVA)

(Real Time Quote from BATS)

$145.51 USD

145.51
75,018

-1.61 (-1.09%)

Updated Jun 3, 2024 10:14 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth F Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 22% (54 out of 250)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.

Reasons to Hold West Pharmaceutical (WST) in Your Portfolio Now

by Zacks Equity Research

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.

Philips (PHG) Expands Sonicare Portfolio With Latest Launch

by Zacks Equity Research

Philips (PHG) adds Philips One for Kids toothbrush into its Sonicare family, boosting its Personal Health business.

BD's (BDX) ADC System Favored by New Study for Long-Term Care

by Zacks Equity Research

BD's (BDX) ADC system is likely to result in improvements in clinical workflow, operational efficiency and financial savings in long-term care facilities.

DaVita HealthCare (DVA) Up 12% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Inari Medical's (NARI) ClotTriever Improves Patient Outcome

by Zacks Equity Research

Inari Medical (NARI) announces two-year interim results from the CLOUT registry, which shows a significant improvement in patient's post-thrombotic syndrome and lower rethrombosis-related events.

Envista (NVST) Faces Macroeconomic Challenges, FX Headwind

by Zacks Equity Research

The challenging macroeconomic conditions are resulting in a significant escalation in Envista's (NVST) costs and expenses.

Inspira Technologies (IINN) Releases Favorable Data on VORTX

by Zacks Equity Research

Inspira Technologies' (IINN) proprietary orbiting oxygenation technology eliminates the need for membrane fibers, thereby reducing pressure differentials and high shear stress.

Here's Why You Should Retain Charles River (CRL) Stock Now

by Zacks Equity Research

Investors remain optimistic about Charles River (CRL) due to the strength of the RMS segment.

New Strong Buy Stocks for March 14th

by Zacks Equity Research

IMMR, NVR, SKWD, DVA and APAM have been added to the Zacks Rank #1 (Strong Buy) List on March 14, 2024.

Chemed's (CHE) VITAS Segment Inks New Deal With Covenant Care

by Zacks Equity Research

Chemed's (CHE) VITAS segment is set to acquire the hospice assets of Covenant Care in Florida and Alabama.

Best Value Stocks to Buy for March 14th

by Zacks Equity Research

IMXI, SKWD and DVA made it to the Zacks Rank #1 (Strong Buy) value stocks list on March 14, 2024.

AMN Healthcare (AMN) Expands Capabilities of ShiftWise Flex

by Zacks Equity Research

AMN Healthcare's (AMN) expansion of the capabilities of ShiftWise Flex is likely to enhance internal resource pool management for the healthcare system.

Philips (PHG), AWS Unite to Scale Digital Pathology Solutions

by Zacks Equity Research

Philips (PHG) collaborates with Amazon Web Services to boost cloud-based pathology solutions. It will enable pathology laboratories to use digital processes to improve analytical capabilities.

PacBio's (PACB) New Panel to Aid Its Clinical Research Solution

by Zacks Equity Research

PacBio (PACB) announces the PureTarget repeat expansion panel, which is the HiFi long-read sequencing that supports comprehensive analysis of 20 genes associated with neurological diseases.

Alcon's (ALC) New Launch Strengthens IOL Innovation Leadership

by Zacks Equity Research

Alcon's (ALC) Clareon platform is available in India in two PCIOL technologies, PanOptix and Vivity.

Here's Why You Should Retain Glaukos (GKOS) Stock for Now

by Zacks Equity Research

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

Orthofix (OFIX) Q4 Earnings Beat Estimates, Gross Margin Up

by Zacks Equity Research

Orthofix's (OFIX) fourth-quarter earnings and revenues beat their respective consensus estimate. Gross margin expands while the company continues to incur losses at the operating level.

Philips (PHG) Aids Personal Health Business With New Campaign

by Zacks Equity Research

Philips (PHG) launches #ShareTheCare brand positioning campaign for Philips Avent, bolstering the Personal Health segment.

ClearPoint's (CLPT) Prism System Favored by Latest Study

by Zacks Equity Research

ClearPoint's (CLPT) Prism Neuro Laser Therapy System is likely to provide an integrated solution for precise and more efficient laser interstitial thermal therapy.

Here's Why You Should Retain BD (BDX) to Your Portfolio

by Zacks Equity Research

BD's (BDX) slew of product launches raises optimism about the stock.

Here's Why You Should Retain Medtronic (MDT) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Medtronic (MDT) on the strength of the Neurosurgery and Cardiovascular and Neurosurgery portfolios.

Bruker (BRKR) Announces Advanced timsTOF Solutions at US HUPO

by Zacks Equity Research

Bruker (BRKR) advances CCS-Enabled 4D-Proteomics timsTOF solutions for immunopeptidomes and glycoproteomics at the US HUPO 2024.

GE HealthCare (GEHC) AI Model to Predict Immunotherapy Response

by Zacks Equity Research

GE HealthCare (GEHC) announces statistics on AI models that collect clinical data to accurately predict the effectiveness and toxicity of cancer immunotherapy.

Thermo Fisher (TMO) Unveils CorEvitas Clinical Registry in GPP

by Zacks Equity Research

Thermo Fisher's (TMO) new CorEvitas clinical registry addresses an unmet need for real-world evidence related to the clinical and patient-reported outcomes of patients with GPP.

Cardinal Health (CAH) Hits 52-Week High: What's Driving It?

by Zacks Equity Research

Investors are optimistic about Cardinal Health's (CAH) diversified product portfolio.